Antibody-Drug Conjugates and Small Molecule-Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents

Journal of Medicinal Chemistry

Volumn 58, Issue 22, 2015, Pages 8751-8761

  Casi, Giulio ^a   Neri, Dario ^b  

^a PHILOCHEM AG   (Switzerland)

^b ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; BRENTUXIMAB VEDOTIN; CYTOTOXIC AGENT; DOXORUBICIN; NIVOLUMAB; TRASTUZUMAB EMTANSINE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; MOLECULAR LIBRARY; MONOCLONAL ANTIBODY;

ANTIBODY DRUG CONJUGATE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER THERAPY; CONJUGATE; HUMAN; NONHUMAN; REVIEW; SMALL MOLECULE DRUG CONJUGATE; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; METABOLISM; MOLECULAR LIBRARY; SYNTHESIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOCONJUGATES; SMALL MOLECULE LIBRARIES;

EID: 84948845426     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00457     Document Type: Review

References (112)

1. Hanna, N. H.; Einhorn, L. H. Testicular cancer-discoveries and updates N. Engl. J. Med. 2014, 371, 2005-2016
2. Szakacs, G.; Paterson, J. K.; Ludwig, J. A.; Booth-Genthe, C.; Gottesman, M. M. Targeting multidrug resistance in cancer Nat. Rev. Drug Discovery 2006, 5, 219-234
3. Bosslet, K.; Straub, R.; Blumrich, M.; Czech, J.; Gerken, M.; Sperker, B.; Kroemer, H. K.; Gesson, J. P.; Koch, M.; Monneret, C. Elucidation of the mechanism enabling tumor selective prodrug monotherapy Cancer Res. 1998, 58, 1195-1201
4. Krall, N.; Scheuermann, J.; Neri, D. Small targeted cytotoxics: Current state and promises from DNA-encoded chemical libraries Angew. Chem., Int. Ed. 2013, 52, 1384-1402
5. van der Veldt, A. A. M.; Hendrikse, N. H.; Smit, E. F.; Mooijer, M. P. J.; Rijnders, A. Y.; Gerritsen, W. R.; van der Hoeven, J. J. M.; Windhorst, A. D.; Lammertsma, A. A.; Lubberink, M. Biodistribution and radiation dosimetry of C-11-labelled docetaxel in cancer patients Eur. J. Nucl. Med. Mol. Imaging 2010, 37, 1950-1958
6. van der Veldt, A. A. M.; Lubberink, M.; Mathijssen, R. H. J.; Loos, W. J.; Herder, G. J. M.; Greuter, H. N.; Comans, E. F. I.; Rutten, H. B.; Eriksson, J.; Windhorst, A. D.; Hendrikse, N. H.; Postmus, P. E.; Smit, E. F.; Lammertsma, A. A. Toward prediction of efficacy of chemotherapy: A proof of concept study in lung cancer patients using C-11 docetaxel and positron emission tomography Clin. Cancer Res. 2013, 19, 4163-4173
7. Chari, R. V. J.; Miller, M. L.; Widdison, W. C. Antibody-drug conjugates: An emerging concept in cancer therapy Angew. Chem., Int. Ed. 2014, 53, 3796-3827
8. Senter, P. D. Potent antibody drug conjugates for cancer therapy Curr. Opin. Chem. Biol. 2009, 13, 235-244
9. Gerber, H.-P.; Senter, P. D.; Grewal, I. S. Antibody drug-conjugates targeting the tumor vasculature. Current and future developments MAbs 2009, 1, 247-253
10. Poli, G. L.; Bianchi, C.; Virotta, G.; Bettini, A.; Moretti, R.; Trachsel, E.; Elia, G.; Giovannoni, L.; Neri, D.; Bruno, A. Radretumab radioimmunotherapy in patients with brain metastasis: A I-124-L19SIP dosimetric PET study Cancer Immunol. Res. 2013, 1, 134-143
11. Erba, P. A.; Sollini, M.; Orciuolo, E.; Traino, C.; Petrini, M.; Paganelli, G.; Bombardieri, E.; Grana, C.; Giovannoni, L.; Neri, D.; Menssen, H. D.; Mariani, G. Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies J. Nucl. Med. 2012, 53, 922-927
12. Stillebroer, A. B.; Zegers, C. M. L.; Boerman, O. C.; Oosterwijk, E.; Mulders, P. F. A.; O'Donoghue, J. A.; Visser, E. P.; Oyen, W. J. G. Dosimetric analysis of Lu-177-cG250 radioimmunotherapy in renal cell carcinoma patients: Correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on In-111-cG250 imaging J. Nucl. Med. 2012, 53, 82-89
13. Sharkey, R. M.; Hajjar, G.; Yeldell, D.; Brenner, A.; Burton, J.; Rubin, A.; Goldenberg, D. M. A phase I trial combining high-dose Y-90-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer J. Nucl. Med. 2005, 46, 620-633
14. Carrasquillo, J. A.; Pandit-Taskar, N.; O'Donoghue, J. A.; Humm, J. L.; Zanzonico, P.; Smith-Jones, P. M.; Divgi, C. R.; Pryma, D. A.; Ruan, S. T.; Kemeny, N. E.; Fong, Y. M.; Wong, D.; Jaggi, J. S.; Scheinberg, D. A.; Gonen, M.; Panageas, K. S.; Ritter, G.; Jungbluth, A. A.; Old, L. J.; Larson, S. M. I-124-huA33 antibody PET of colorectal cancer J. Nucl. Med. 2011, 52, 1173-1180
15. Borjesson, P. K. E.; Jauw, Y. W. S.; de Bree, R.; Roos, J. C.; Castelijns, J. A.; Leemans, C. R.; van Dongen, G. A. M. S.; Boellaard, R. Radiation dosimetry of Zr-89-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients J. Nucl. Med. 2009, 50, 1828-1836
16. Muselaers, C. H. J.; Stillebroer, A. B.; Desar, I. M. E.; Boers-Sonderen, M. J.; van Herpen, C. M. L.; de Weijert, M. C. A.; Langenhuijsen, J. F.; Oosterwijk, E.; Leenders, W. P. J.; Boerman, O. C.; Mulders, P. F. A.; Oyen, W. J. G. Tyrosine kinase inhibitor sorafenib decreases In-111-girentuximab uptake in patients with clear cell renal cell carcinoma J. Nucl. Med. 2014, 55, 242-247
17. Breitz, H. B.; Tyler, A.; Bjorn, M. J.; Lesley, T.; Weiden, P. L. Clinical experience with Tc-99m nofetumomab merpentan (Verluma) radioimmunoscintigraphy Clin. Nucl. Med. 1997, 22, 615-620
18. Heuveling, D. A.; de Bree, R.; Vugts, D. J.; Huisman, M. C.; Giovannoni, L.; Hoekstra, O. S.; Leemans, C. R.; Neri, D.; van Dongen, G. A. M. S. Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients J. Nucl. Med. 2013, 54, 397-401
19. Ychou, M.; Pelegrin, A.; Faurous, P.; Robert, B.; Saccavini, J. C.; Guerreau, D.; Rossi, J. F.; Fabbro, M.; Buchegger, F.; Mach, J. P.; Artus, J. C. Phase-I/II radio-immunotherapy study with iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab′)2 in patients with non-resectable liver metastases from colorectal cancer Int. J. Cancer 1998, 75, 615-619
20. Wu, A. M.; Senter, P. D. Arming antibodies: prospects and challenges for immunoconjugates Nat. Biotechnol. 2005, 23, 1137-1146
21. Borsi, L.; Balza, E.; Bestagno, M.; Castellani, P.; Carnemolla, B.; Biro, A.; Leprini, A.; Sepulveda, J.; Burrone, O.; Neri, D.; Zardi, L. Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin Int. J. Cancer 2002, 102, 75-85
22. Berndorff, D.; Borkowski, S.; Sieger, S.; Rother, A.; Friebe, M.; Viti, F.; Hilger, C. S.; Cyr, J. E.; Dinkelborg, L. M. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: Identification of the best-suited radioimmunoconjugate Clin. Cancer Res. 2005, 11, 7053S-7063S
23. Moreau, M.; Raguin, O.; Vrigneaud, J. M.; Collin, B.; Bernhard, C.; Tizon, X.; Boschetti, F.; Duchamp, O.; Brunotte, F.; Denat, F. DOTAGA-trastuzumab. A new antibody conjugate targeting HER2/Neu antigen for diagnostic purposes Bioconjugate Chem. 2012, 23, 1181-1188
24. Brouwers, A. H.; van Eerd, J. E. M.; Frielink, C.; Oosterwijk, E.; Oyen, W. J. G.; Corstens, F. H. M.; Boerman, O. C. Optimization of radioimmunotherapy of renal cell carcinoma: Labeling of monoclonal antibody cG250 with I-131, Y-90, Lu-177, or Re-186 J. Nucl. Med. 2004, 45, 327-337
25. Dennis, M. S.; Jin, H.; Dugger, D.; Yang, R.; McFarland, L.; Ogasawara, A.; Williams, S.; Cole, M. J.; Ross, S.; Schwall, R. Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent Cancer Res. 2007, 67, 254-261
26. Saga, T.; Neumann, R. D.; Heya, T.; Sato, J.; Kinuya, S.; Le, N.; Paik, C. H.; Weinstein, J. N. Targeting cancer micrometastases with monoclonal-antibodies-A binding-site barrier Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 8999-9003
27. Adams, G. P.; Schier, R.; McCall, A. M.; Simmons, H. H.; Horak, E. M.; Alpaugh, R. K.; Marks, J. D.; Weiner, L. M. High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules Cancer Res. 2001, 61, 4750-4755
28. Rudnick, S. I.; Lou, J. L.; Shaller, C. C.; Tang, Y.; Klein-Szanto, A. J. P.; Weiner, L. M.; Marks, J. D.; Adams, G. P. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors Cancer Res. 2011, 71, 2250-2259
29. Trail, P. A.; Willner, D.; Lasch, S. J.; Henderson, A. J.; Hofstead, S.; Casazza, A. M.; Firestone, R. A.; Hellström, I.; Hellström, K. E. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates Science 1993, 261, 212-215
30. Lowinger, T. B. Applications of biodegradable and biocompatible polyacetal drug conjugates to improve drug delivery. Abstracts of Papers-American Chemical Society; American Chemical Society: Washington, DC, 2010.
31. de Claro, R. A.; McGinn, K.; Kwitkowski, V.; Bullock, J.; Khandelwal, A.; Habtemariam, B.; Ouyang, Y. L.; Saber, H.; Lee, K.; Koti, K.; Rothmann, M.; Shapiro, M.; Borrego, F.; Clouse, K.; Chen, X. H.; Brown, J.; Akinsanya, L.; Kane, R.; Kaminskas, E.; Farrell, A.; Pazdur, R. U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma Clin. Cancer Res. 2012, 18, 5845-5849
32. Erickson, H. K.; Park, P. U.; Widdison, W. C.; Kovtun, Y. V.; Garrett, L. M.; Hoffman, K.; Lutz, R. J.; Goldmacher, V. S.; Blättler, W. A. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing Cancer Res. 2006, 66, 4426-4433
33. Kovtun, Y. V.; Audette, C. A.; Mayo, M. F.; Jones, G. E.; Doherty, H.; Maloney, E. K.; Erickson, H. K.; Sun, X. X.; Wilhelm, S.; Ab, O.; Lai, K. C.; Widdison, W. C.; Kellogg, B.; Johnson, H.; Pinkas, J.; Lutz, R. J.; Singh, R.; Goldmacher, V. S.; Chari, R. V. J. Antibody-maytansinoid conjugates designed to bypass multidrug resistance Cancer Res. 2010, 70, 2528-2537
34. Chudasama, V. L.; Stark, F. S.; Harrold, J. M.; Tibbitts, J.; Girish, S. R.; Gupta, M.; Frey, N.; Mager, D. E. Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer Clin. Pharmacol. Ther. 2012, 92, 520-527
35. Peddi, P. F.; Hurvitz, S. A. Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer Future Oncol. 2013, 9, 319-326
36. Phillips, G. D. L.; Li, G.; Dugger, D. L.; Crocker, L. M.; Parsons, K. L.; Mai, E.; Blattler, W. A.; Lambert, J. M.; Chari, R. V. J.; Lutz, R. J.; Wong, W. L. T.; Jacobson, F. S.; Koeppen, H.; Schwall, R. H.; Kenkare-Mitra, S. R.; Spencer, S. D.; Sliwkowski, M. X. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate Cancer Res. 2008, 68, 9280-9290
37. Tian, F.; Lu, Y. C.; Manibusan, A.; Sellers, A.; Tran, H.; Sun, Y.; Phuong, T.; Barnett, R.; Hehli, B.; Song, F.; DeGuzman, M. J.; Ensari, S.; Pinkstaff, J. K.; Sullivan, L. M.; Biroc, S. L.; Cho, H.; Schultz, P. G.; DiJoseph, J.; Dougher, M.; Ma, D. S.; Dushin, R.; Leal, M.; Tchistiakova, L.; Feyfant, E.; Gerber, H. P.; Sapra, P. A general approach to site-specific antibody drug conjugates Proc. Natl. Acad. Sci. U.S.A. 2014, 111, 1766-1771
38. Shen, B.-Q.; Xu, K.; Liu, L.; Raab, H.; Bhakta, S.; Kenrick, M.; Parsons-Reponte, K. L.; Tien, J.; Yu, S.-F.; Mai, E.; Li, D.; Tibbitts, J.; Baudys, J.; Saadi, O. M.; Scales, S. J.; McDonald, P. J.; Hass, P. E.; Eigenbrot, C.; Trung, N.; Solis, W. A.; Fuji, R. N.; Flagella, K. M.; Patel, D.; Spencer, S. D.; Khawlil, L. A.; Ebens, A.; Wong, W. L.; Vandlen, R.; Kaur, S.; Sliwkowski, M. X.; Scheller, R. H.; Polakis, P.; Junutula, J. R. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates Nat. Biotechnol. 2012, 30, 184-189
39. Junutula, J. R.; Flagella, K. M.; Graham, R. A.; Parsons, K. L.; Ha, E.; Raab, H.; Bhakta, S.; Nguyen, T.; Dugger, D. L.; Li, G. M.; Mai, E.; Phillips, G. D. L.; Hiraragi, H.; Fuji, R. N.; Tibbitts, J.; Vandlen, R.; Spencer, S. D.; Scheller, R. H.; Polakis, P.; Sliwkowski, M. X. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer Clin. Cancer Res. 2010, 16, 4769-4778
40. Junutula, J. R.; Raab, H.; Clark, S.; Bhakta, S.; Leipold, D. D.; Weir, S.; Chen, Y.; Simpson, M.; Tsai, S. P.; Dennis, M. S.; Lu, Y.; Meng, Y. G.; Ng, C.; Yang, J.; Lee, C. C.; Duenas, E.; Gorrell, J.; Katta, V.; Kim, A.; McDorman, K.; Flagella, K.; Venook, R.; Ross, S.; Spencer, S. D.; Wong, W. L.; Lowman, H. B.; Vandlen, R.; Sliwkowski, M. X.; Scheller, R. H.; Polakis, P.; Mallet, W. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index Nat. Biotechnol. 2008, 26, 925-932
41. Boghaert, E. R.; Khandke, K.; Sridharan, L.; Armellino, D.; Dougher, M.; DiJoseph, J. F.; Kunz, A.; Hamann, P. R.; Sridharan, A.; Jones, S.; Discafani, C.; Damle, N. K. Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy Int. J. Oncol. 2006, 28, 675-684
42. Jedema, I.; Barge, R. M. Y.; van der Velden, V. H. J.; Nijmeijer, B. A.; van Dongen, J. J. M.; Willemze, R.; Falkenburg, J. H. F. Internalization and cell cycle-dependent killing of leukemic cells by gemtuzumab ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity Leukemia 2004, 18, 316-325
43. Farhat, H.; Reman, O.; Raffoux, E.; Berthon, C.; Pautas, C.; Kammoun, L.; Chantepie, S.; Gardin, C.; Rousselot, P.; Chevret, S.; Dombret, H.; Castaigne, S. Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: A phase 1/2 study of the acute leukemia French association Am. J. Hematol 2012, 87, 62-65
44. Taksin, A. L.; Legrand, O.; Raffoux, E.; de Revel, T.; Thomas, X.; Contentin, N.; Bouabdallah, R.; Pautas, C.; Turlure, P.; Reman, O.; Gardin, C.; Varet, B.; de Botton, S.; Pousset, F.; Farhat, H.; Chevret, S.; Dombret, H.; Castaigne, S. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group Leukemia 2007, 21, 66-71
45. Burnett, A. K.; Hills, R. K.; Milligan, D.; Kjeldsen, L.; Kell, J.; Russell, N. H.; Yin, J. A. L.; Hunter, A.; Goldstone, A. H.; Wheatley, K. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 trial J. Clin. Oncol. 2011, 29, 369-377
46. Burnett, A. K.; Russell, N. H.; Hills, R. K.; Kell, J.; Freeman, S.; Kjeldsen, L.; Hunter, A. E.; Yin, J.; Craddock, C. F.; Dufva, I. H.; Wheatley, K.; Milligan, D. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia J. Clin. Oncol. 2012, 30, 3924-3931
47. Castaigne, S.; Pautas, C.; Terre, C.; Raffoux, E.; Bordessoule, D.; Bastie, J. N.; Legrand, O.; Thomas, X.; Turlure, P.; Reman, O.; de Revel, T.; Gastaud, L.; de Gunzburg, N.; Contentin, N.; Henry, E.; Marolleau, J. P.; Aljijakli, A.; Rousselot, P.; Fenaux, P.; Preudhomme, C.; Chevret, S.; Dombret, H.; Acute Leukemia French Association Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study Lancet 2012, 379, 1508-1516
48. Delaunay, J.; Recher, C.; Pigneux, A.; Witz, F.; Vey, N.; Blanchet, O.; Lefebvre, P.; Luquet, I.; Guillerme, I.; Volteau, C.; Gyan, E.; Lioure, B.; Jourdan, E.; Bouscary, D.; Guieze, R.; Randriamalala, E.; Uribe, M. E. O.; Dreyfus, F.; Lacombe, C.; Bene, M. C.; Cahn, J. Y.; Harousseau, J. L.; Ifrah, N. Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR study Blood 2011, 118, 37-38
49. Sutherland, M. S. K.; Walter, R. B.; Jeffrey, S. C.; Burke, P. J.; Yu, C. P.; Kostner, H.; Stone, I.; Ryan, M. C.; Sussman, D.; Lyon, R. P.; Zeng, W. P.; Harrington, K. H.; Klussman, K.; Westendorf, L.; Meyer, D.; Bernstein, I. D.; Senter, P. D.; Benjamin, D. R.; Drachman, J. G.; McEarchern, J. A. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML Blood 2013, 122, 1455-1463
50. Bander, N. H. Antibody-drug conjugate target selection: critical factors. In Methods in Molecular Biology: Antibody-Drug Conjugates; Ducry, L., Ed.; Humana Press: New York, 2013; Vol. 1045, pp 29-40.
51. Tarli, L.; Balza, E.; Viti, F.; Borsi, L.; Castellani, P.; Berndorff, D.; Dinkelborg, L.; Neri, D.; Zardi, L. A high-affinity human antibody that targets tumoral blood vessels Blood 1999, 94, 192-198
52. Viti, F.; Tarli, L.; Giovannoni, L.; Zardi, L.; Neri, D. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis Cancer Res. 1999, 59, 347-352
53. Pini, A.; Viti, F.; Santucci, A.; Carnemolla, B.; Zardi, L.; Neri, P.; Neri, D. Design and use of a phage display library-Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel J. Biol. Chem. 1998, 273, 21769-21776
54. Villa, A.; Trachsel, E.; Kaspar, M.; Schliemann, C.; Sommavilla, R.; Rybak, J.-N.; Rösli, C.; Borsi, L.; Neri, D. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo Int. J. Cancer 2008, 122, 2405-2413
55. Neri, D.; Bicknell, R. Tumour vascular targeting Nat. Rev. Cancer 2005, 5, 436-446
56. Perrino, E.; Steiner, M.; Krall, N.; Bernardes, G. J. L.; Pretto, F.; Casi, G.; Neri, D. Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids Cancer Res. 2014, 74, 2569-2578
57. Bernardes, G. J. L.; Casi, G.; Hartmann, I.; Trüssel, S.; Schwager, K.; Scheuermann, J.; Neri, D. A traceless vascular-targeting antibody-drug conjugate for cancer therapy Angew. Chem., Int. Ed. 2012, 51, 941-944
58. Krall, N.; Pretto, F.; Decurtins, W.; Bernardes, G. J. L.; Supuran, C. T.; Neri, D. A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors Angew. Chem., Int. Ed. 2014, 53, 4231-4235
59. Rothberg, J. M.; Bailey, K. M.; Wojtkowiak, J. W.; Ben-Nun, Y.; Bogyo, M.; Weber, E.; Moin, K.; Blum, G.; Mattingly, R. R.; Gillies, R. J.; Sloane, B. F. Acid-mediated tumor proteolysis: Contribution of cysteine cathepsins Neoplasia 2013, 15, 1111-1123
60. Fuhrmann, K.; Gauthier, M. A.; Leroux, J. C. Targeting of injectable drug nanocrystals Mol. Pharmaceutics 2014, 11, 1762-1771
61. Winter, G.; Griffiths, A. D.; Hawkins, R. E.; Hoogenboom, H. R. Making antibodies by phage display technology Annu. Rev. Immunol. 1994, 12, 433-455
62. Srinivasarao, M.; Galliford, C. V.; Low, P. S. Principles in the design of ligand-targeted cancer therapeutics and imaging agents Nat. Rev. Drug Discovery 2015, 14, 203-219
63. Low, P. S.; Henne, W. A.; Doorneweerd, D. D. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases Acc. Chem. Res. 2008, 41, 120-129
64. Hillier, S. M.; Maresca, K. P.; Femia, F. J.; Marquis, J. C.; Foss, C. A.; Nguyen, N.; Zimmerman, C. N.; Barrett, J. A.; Eckelman, W. C.; Pomper, M. G.; Joyal, J. L.; Babich, J. W. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer Cancer Res. 2009, 69, 6932-6940
65. Vallabhajosula, S.; Nikolopoulou, A.; Babich, J. W.; Osborne, J. R.; Tagawa, S. T.; Lipai, I.; Solnes, L.; Maresca, K. P.; Armor, T.; Joyal, J. L.; Crummet, R.; Stubbs, J. B.; Goldsmith, S. J. Tc-99m-labeled small-molecule inhibitors of prostate-specific membrane antigen: Pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer J. Nucl. Med. 2014, 55, 1791-1798
66. Hillier, S. M.; Maresca, K. P.; Lu, G.; Merkin, R. D.; Marquis, J. C.; Zimmerman, C. N.; Eckelman, W. C.; Joyal, J. L.; Babich, J. W. Tc-99m-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer J. Nucl. Med. 2013, 54, 1369-1376
67. Ginj, M.; Zhang, H.; Waser, B.; Cescato, R.; Wild, D.; Wang, X.; Erchegyi, J.; Rivier, J.; Maecke, H. R.; Reubi, J. C. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 16436-16441
68. Neri, D.; Supuran, C. T. Interfering with pH regulation in tumours as a therapeutic strategy Nat. Rev. Drug Discovery 2011, 10, 767-777
69. Krall, N.; Pretto, F.; Neri, D. A bivalent small molecule-drug conjugate directed against carbonic anhydrase IX can elicit complete tumour regression in mice Chem. Sci. 2014, 5, 3640-3644
70. Wichert, M.; Krall, N.; Decurtins, W.; Franzini, R. M.; Pretto, F.; Schneider, P.; Neri, D.; Scheuermann, J. Dual-display of small molecules enables the discovery of ligand pairs and facilitates affinity maturation Nat. Chem. 2015, 7, 241-249
71. Doss, M.; Kolb, H. C.; Walsh, J. C.; Mocharla, V. P.; Zhu, Z. H.; Haka, M.; Alpaugh, R. K.; Chen, D. Y. T.; Yu, J. Q. Biodistribution and radiation dosimetry of the carbonic anhydrase IX imaging agent [(18) F]VM4-037 determined from PET/CT scans in healthy volunteers Mol. Imaging Biol. 2014, 16, 739-746
72. Lepenies, B.; Lee, J.; Sonkaria, S. Targeting C-type lectin receptors with multivalent carbohydrate ligands Adv. Drug Delivery Rev. 2013, 65, 1271-1281
73. Chittasupho, C. Multivalent ligand: design principle for targeted therapeutic delivery approach Ther. Delivery 2012, 3, 1171-1187
74. Guillemard, V.; Nedev, H. N.; Berezov, A.; Murali, R.; Saragovi, H. U. HER2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand DNA Cell Biol. 2005, 24, 350-358
75. Daguer, J. P.; Zambaldo, C.; Ciobanu, M.; Morieux, P.; Barluenga, S.; Winssinger, N. DNA display of fragment pairs as a tool for the discovery of novel biologically active small molecules Chem. Sci. 2015, 6, 739-744
76. Franzini, R. M.; Neri, D.; Scheuermann, J. DNA-encoded chemical libraries: Advancing beyond conventional small-molecule libraries Acc. Chem. Res. 2014, 47, 1247-1255
77. Chan, A. I.; McGregor, L. M.; Liu, D. R. Novel selection methods for DNA-encoded chemical libraries Curr. Opin. Chem. Biol. 2015, 26C, 55-61
78. Morioka, T.; Loik, N. D.; Hipolito, C. J.; Goto, Y.; Suga, H. Selection-based discovery of macrocyclic peptides for the next generation therapeutics Curr. Opin Chem. Biol. 2015, 26C, 34-41
79. Heinis, C.; Rutherford, T.; Freund, S.; Winter, G. Phage-encoded combinatorial chemical libraries based on bicyclic peptides Nat. Chem. Biol. 2009, 5, 502-507
80. Parker, N.; Turk, M. J.; Westrick, E.; Lewis, J. D.; Low, P. S.; Leamon, C. P. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay Anal. Biochem. 2005, 338, 284-293
81. Morris, R. T.; Joyrich, R. N.; Naumann, R. W.; Shah, N. P.; Maurer, A. H.; Strauss, H. W.; Uszler, J. M.; Symanowski, J. T.; Ellis, P. R.; Harb, W. A. Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (Tc-99m-etarfolatide) Ann. Oncol 2014, 25, 852-858
82. Naumann, R. W.; Coleman, R. L.; Burger, R. A.; Sausville, E. A.; Kutarska, E.; Ghamande, S. A.; Gabrail, N. Y.; Depasquale, S. E.; Nowara, E.; Gilbert, L.; Gersh, R. H.; Teneriello, M. G.; Harb, W. A.; Konstantinopoulos, P. A.; Penson, R. T.; Symanowski, J. T.; Lovejoy, C. D.; Leamon, C. P.; Morgenstern, D. E.; Messmann, R. A. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer J. Clin. Oncol. 2013, 31, 4400-4406
83. LoRusso, P. M.; Edelman, M. J.; Bever, S. L.; Forman, K. M.; Pilat, M.; Quinn, M. F.; Li, J.; Heath, E. I.; Malburg, L. M.; Klein, P. J.; Leamon, C. P.; Messmann, R. A.; Sausville, E. A. Phase I study of folate conjugate EC145 (vintafolide) in patients with refractory solid tumors J. Clin. Oncol. 2012, 30, 4011-4016
84. Uhlen, M.; Fagerberg, L.; Hallstrom, B. M.; Lindskog, C.; Oksvold, P.; Mardinoglu, A.; Sivertsson, A.; Kampf, C.; Sjostedt, E.; Asplund, A.; Olsson, I.; Edlund, K.; Lundberg, E.; Navani, S.; Szigyarto, C. A.; Odeberg, J.; Djureinovic, D.; Takanen, J. O.; Hober, S.; Alm, T.; Edqvist, P. H.; Berling, H.; Tegel, H.; Mulder, J.; Rockberg, J.; Nilsson, P.; Schwenk, J. M.; Hamsten, M.; von Feilitzen, K.; Forsberg, M.; Persson, L.; Johansson, F.; Zwahlen, M.; von Heijne, G.; Nielsen, J.; Ponten, F. Proteomics. Tissue-based map of the human proteome Science 2015, 347, 394
85. Uhlen, M.; Oksvold, P.; Fagerberg, L.; Lundberg, E.; Jonasson, K.; Forsberg, M.; Zwahlen, M.; Kampf, C.; Wester, K.; Hober, S.; Wernerus, H.; Bjorling, L.; Ponten, F. Towards a knowledge-based human protein atlas Nat. Biotechnol. 2010, 28, 1248-1250
86. Zechmann, C. M.; Afshar-Oromieh, A.; Armor, T.; Stubbs, J. B.; Mier, W.; Hadaschik, B.; Joyal, J.; Kopka, K.; Debus, J.; Babich, J. W.; Haberkorn, U. Radiation dosimetry and first therapy results with a I-124/I-131-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy Eur. J. Nucl. Med. Mol. Imaging 2014, 41, 1280-1292
87. Silver, D. A.; Pellicer, I.; Fair, W. R.; Heston, W. D. W.; CordonCardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues Clin. Cancer Res. 1997, 3, 81-85
88. Israeli, R. S.; Powell, C. T.; Fair, W. R.; Heston, W. D. W. Molecular-cloning of a complementary-DNA encoding a prostate-specific membrane antigen Cancer Res. 1993, 53, 227-230
89. Chang, S. S.; Reuter, V. E.; Heston, W. D. W.; Bander, N. H.; Grauer, L. S.; Gaudin, P. B. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature Cancer Res. 1999, 59, 3192-3198
90. Liu, H.; Moy, P.; Kim, S.; Xia, Y.; Rajasekaran, A.; Navarro, V.; Knudsen, B.; Bander, N. H. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium Cancer Res. 1997, 57, 3629-3634
91. De Simone, G.; Alterio, V.; Supuran, C. T. Exploiting the hydrophobic and hydrophilic binding sites for designing carbonic anhydrase inhibitors Expert Opin. Drug Discovery 2013, 8, 793-810
92. Thiry, A.; Dogne, J. M.; Masereel, B.; Supuran, C. T. Targeting tumor-associated carbonic anhydrase IX in cancer therapy Trends Pharmacol. Sci. 2006, 27, 566-573
93. Bui, M. H.; Seligson, D.; Han, K. R.; Pantuck, A. J.; Dorey, F. J.; Huang, Y.; Horvath, S.; Leibovich, B. C.; Chopra, S.; Liao, S. Y.; Stanbridge, E.; Lerman, M. I.; Palotie, A.; Figlin, R. A.; Belldegrun, A. S. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy Clin. Cancer Res. 2003, 9, 802-811
94. Svastova, E.; Hulikova, A.; Rafajova, M.; Zat'ovicova, M.; Gibadulinova, A.; Casini, A.; Cecchi, A.; Scozzafava, A.; Supuran, C. T.; Pastorek, J.; Pastorekova, S. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH FEBS Lett. 2004, 577, 439-445
95. Scheurer, S. B.; Rybak, J. N.; Rosli, C.; Neri, D.; Elia, G. Modulation of gene expression by hypoxia in human umbilical cord vein endothelial cells: A transcriptomic and proteomic study Proteomics 2004, 4, 1737-1760
96. Petrul, H. M.; Schatz, C. A.; Kopitz, C. C.; Adnane, L.; McCabe, T. J.; Trail, P.; Ha, S.; Chang, Y. S.; Voznesensky, A.; Ranges, G.; Tamburini, P. P. Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9 Mol. Cancer. Ther. 2012, 11, 340-349
97. Dubois, L.; Lieuwes, N. G.; Maresca, A.; Thiry, A.; Supuran, C. T.; Scozzafava, A.; Wouters, B. G.; Lambin, P. Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model Radiother. Oncol. 2009, 92, 423-428
98. Maurer, A. H.; Elsinga, P.; Fanti, S.; Nguyen, B.; Oyen, W. J. G.; Weber, W. A. Imaging the folate receptor on cancer cells with Tc-99m-etarfolatide: Properties, clinical use, and future potential of folate receptor imaging J. Nucl. Med. 2014, 55, 701-704
99. Kularatne, S. A.; Wang, K.; Santhapuram, H. K. R.; Low, P. S. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand Mol. Pharmaceutics 2009, 6, 780-789
100. Cohen, R.; Vugts, D. J.; Visser, G. W. M.; Stigter-Van Walsum, M.; Bolijn, M.; Spiga, M.; Lazzari, P.; Shankar, E.; Sani, M.; Zanda, M.; Van Dongen, G. A. M. S. Development of novel ADCs: Conjugation of tubulysin analogues to trastuzumab monitored by dual radiolabeling Cancer Res. 2014, 74, 5700-5710
101. Erez, R.; Segal, E.; Miller, K.; Satchi-Fainaro, R.; Shabat, D. Enhanced cytotoxicity of a polymer-drug conjugate with triple payload of paclitaxel Bioorg. Med. Chem. 2009, 17, 4327-4335
102. Ojima, I. Guided molecular missiles for tumor-targeting chemotherapy-case studies using the second-generation taxolds as warheads Acc. Chem. Res. 2008, 41, 108-119
103. Weinstain, R.; Segal, E.; Satchi-Fainaro, R.; Shabat, D. Real-time monitoring of drug release Chem. Commun. 2010, 46, 553-555
104. Bernardes, G. J. L.; Steiner, M.; Hartmann, I.; Neri, D.; Casi, G. Site-specific chemical modification of antibody fragments using traceless cleavable linkers Nat. Protoc. 2013, 8, 2079-2089
105. Casi, G.; Huguenin-Dezot, N.; Zuberbühler, K.; Scheuermann, J.; Neri, D. Site-specific traceless coupling of potent cytotoxic drugs to recombinant antibodies for pharmacodelivery J. Am. Chem. Soc. 2012, 134, 5887-5892
106. Santi, D. V.; Schneider, E. L.; Reid, R.; Robinson, L.; Ashley, G. W. Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 6211-6216
107. Strop, P.; Liu, S. H.; Dorywalska, M.; Delaria, K.; Dushin, R. G.; Tran, T. T.; Ho, W. H.; Farias, S.; Casas, M. G.; Abdiche, Y.; Zhou, D.; Chandrasekaran, R.; Samain, C.; Loo, C.; Rossi, A.; Rickert, M.; Krimm, S.; Wong, T.; Chin, S. M.; Yu, J.; Dilley, J.; Chaparro-Riggers, J.; Filzen, G. F.; O'Donnell, C. J.; Wang, F.; Myers, J. S.; Pons, J.; Shelton, D. L.; Rajpal, A. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates Chem. Biol. 2013, 20, 161-167
108. Muller, C.; Schibli, R. Prospects in folate receptor-targeted radionuclide therapy Front. Oncol. 2013, 3, 249
109. Gutbrodt, K. L.; Casi, G.; Neri, D. Antibody-based delivery of IL2 and cytotoxics eradicates tumors in immunocompetent mice Mol. Cancer Ther. 2014, 13, 1772-1776
110. List, T.; Casi, G.; Neri, D. A chemically defined trifunctional antibody-cytokine-drug conjugate with potent antitumor activity Mol. Cancer Ther. 2014, 13, 2641-2652
111. Wittrup, K. D.; Thurber, G. M.; Schmidt, M. M.; Rhoden, J. J. Practical theoretic guidance for the design of tumor-targeting agents Methods Enzymol. 2012, 503, 255-268
112. Tzeng, A.; Kwan, B. H.; Opel, C. F.; Navaratna, T.; Wittrup, K. D. Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution Proc. Natl. Acad. Sci. U.S.A. 2015, 112, 3320-3325